Alali Zainab, Ferdous Umme Tamanna, Nzila Alexis, Easmin Farhana, Shakoor Adnan, Zia Abdul Wasy, Uddin Shihab
Department of Bioengineering, King Fahd University of Petroleum & Minerals, 31261, Dhahran, Saudi Arabia.
Center for Biosystems and Machines, King Fahd University of Petroleum & Minerals, 31261, Dhahran, Saudi Arabia.
Stem Cell Rev Rep. 2025 Oct;21(7):1931-1954. doi: 10.1007/s12015-025-10933-5. Epub 2025 Jul 12.
Stem cell-based immunotherapy represents a groundbreaking advancement in cancer treatment, leveraging the immune system's inherent capacity to target and eradicate cancer cells. This review explores some of the examples of stem cells used in cancer immunotherapy, including hematopoietic, mesenchymal, and induced pluripotent stem cells (IPSCs). It also describes stem cell functionalities like modifying tumor microenvironment (TME) and developing engineered immune cells like chimeric antigen receptor (CAR)-T cells and natural killer (NK) cells. Additionally, the clinical applications of stem cells for improving cancer immunotherapies and delivering drugs directly to solid tumors are discussed. However, several challenges limit the effectiveness of stem cell technology, including safety risks, tumor avoidance by the immune system, and regulatory protocols as well as manufacturing barriers. This article reviews current advancements to overcome these challenges, such as CRISPR-based gene editing and targeted drug delivery systems and provides an outlook on emerging trends, such as the progress of personalized stem cell therapies and the increasing effectiveness of treatment by combining them with other cancer treatments.
基于干细胞的免疫疗法是癌症治疗领域的一项突破性进展,它利用免疫系统固有的靶向和根除癌细胞的能力。本综述探讨了用于癌症免疫疗法的一些干细胞实例,包括造血干细胞、间充质干细胞和诱导多能干细胞(iPSC)。它还描述了干细胞的功能,如改变肿瘤微环境(TME)以及开发工程化免疫细胞,如嵌合抗原受体(CAR)-T细胞和自然杀伤(NK)细胞。此外,还讨论了干细胞在改善癌症免疫疗法和直接向实体瘤递送药物方面的临床应用。然而,一些挑战限制了干细胞技术的有效性,包括安全风险、免疫系统对肿瘤的逃避、监管协议以及制造障碍。本文综述了克服这些挑战的当前进展,如基于CRISPR的基因编辑和靶向药物递送系统,并展望了新兴趋势,如个性化干细胞疗法的进展以及将它们与其他癌症治疗方法相结合所带来的治疗效果的提高。